Case 1:22-cv-00252-MSG Document 193-8 Filed 01/16/24 Page 1 of 3 PageID #: 12612
`Case 1:22-cv-00252-MSG Document 193-8 Filed 01/16/24 Page 1 of 3 PagelD #: 12612
`
`EXHIBIT 8
`EXHIBIT 8
`
`

`

`Case 1:22-cv-00252-MSG Document 193-8 Filed 01/16/24 Page 2 of 3 PageID #: 12613
`
`Sheh, Anthony
`Dean, Caitlin; Genevant Team; Arbutus MoFo
`#KEModernaSpikevaxService; Blumenfeld, Jack; Egan, Brian P.; Murray, Travis; "kkeller@shawkeller.com";
`"nhoeschen@shawkeller.com"; *jshaw@shawkeller.com
`RE: Arbutus v. Moderna, 1-22-cv 00252 - Moderna"s RFP No. 106
`Thursday, November 30, 2023 6:28:45 PM
`
`From:
`To:
`Cc:
`
`Subject:
`Date:
`
`Caitlin,
`
`We’ve repeatedly explained the challenge and burden on our end regarding INDs due to the lack of a
`centralized database of regulatory submissions. The burden of conducting a search among loose
`files is both undue and disproportionate relative to the minimal relevance that Moderna has
`identified to date.
`
`Nevertheless, Plaintiffs will agree to conduct a reasonable and proportionate search for IND
`documents that you requested in your November 29, 2023 email within the scope of the asserted
`patents—as we have flagged before, we can make no guarantees that we will be able to locate a
`complete set of responsive documents, the draft or final status of the documents, whether they
`were ever submitted to FDA, etc. We are unsure of exactly when we will be able make a production,
`but will work diligently to provide what we can responsive to Moderna’s request.
`
`We understand that it remains Moderna’s position that it refuses to search for its own INDs within
`the scope of the asserted patents responsive to Plaintiffs’ RFPs 164–167 despite (1) those
`documents being readily available in a regulatory document database, (2) Moderna’s repeated
`insistence that Plaintiffs produce equivalent documents, and (3) Plaintiffs’ previously expressed
`willingness to narrow these RFPs to remove Module 5. Plaintiffs intend to seek the Court’s
`assistance to obtain these highly relevant documents.
`
`Best,
`Tony
`
`Anthony Sheh | Associate | Williams & Connolly LLP | (202) 434-5436 | vcard
`
`From: Dean, Caitlin <caitlin.dean@kirkland.com>
`Sent: Wednesday, November 29, 2023 5:27 PM
`To: Sheh, Anthony <ASheh@wc.com>; Genevant Team <GenevantTeam@wc.com>; Arbutus_MoFo
`<Arbutus_MoFo@mofo.com>
`Cc: #KEModernaSpikevaxService <KEModernaSpikevaxService@kirkland.com>; Blumenfeld, Jack
`<JBlumenfeld@morrisnichols.com>; Egan, Brian P. <began@morrisnichols.com>; Murray, Travis
`<tmurray@morrisnichols.com>; 'kkeller@shawkeller.com' <kkeller@shawkeller.com>;
`'nhoeschen@shawkeller.com' <nhoeschen@shawkeller.com>; *jshaw@shawkeller.com
`<jshaw@shawkeller.com>
`Subject: Arbutus v. Moderna, 1-22-cv 00252 - Moderna's RFP No. 106
`
`Counsel,
`
`

`

`Case 1:22-cv-00252-MSG Document 193-8 Filed 01/16/24 Page 3 of 3 PageID #: 12614
`
`Pursuant to your offer to compromise on yesterday’s meet-and-confer regarding Moderna’s RFP No.
`106, will Plaintiffs agree to produce INDs sponsored by Plaintiffs or their predecessors for products
`within the scope of the Patents-in-Suit excluding Module 5? As you know, Moderna agreed to
`produce FDA filings for the Accused Product, including correspondence and all Modules except
`Module 5. Please let us know or confirm that the parties are at an impasse by Friday, December 1,
`2023.
`
`Best,
`Caitlin
`
`Caitlin Dean
`-----------------------------------------------------
`KIRKLAND & ELLIS LLP
`601 Lexington Ave, New York, NY 10022
`T +1 212 909 3099 M +1 929 262 2212
`F +1 212 446 4900
`-----------------------------------------------------
`caitlin.dean@kirkland.com
`
`The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside
`information, and is intended only for the use of the addressee. It is the property of Kirkland & Ellis LLP or Kirkland & Ellis
`International LLP. Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and
`may be unlawful. If you have received this communication in error, please notify us immediately by return email or by email
`to postmaster@kirkland.com, and destroy this communication and all copies thereof, including all attachments.
`
`